
Opinion|Videos|May 29, 2024
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Addressing Burnout in Pharmacy Residency: A Comprehensive Approach to Enhancing Well-Being
4
CHEST 2025: Advancing Respiratory Virus Vaccines and Improving Uptake Among High-Risk Populations
5

















































































































































































































